In this review:
Optimal duration of extended letrozole treatment; results of the randomized phase III IDEAL trial (BOOG 2006-05)
Hypo- vs normofractionated radiation therapy of early stage breast cancer in the DBCG HYPO trial
Sixteen months follow-up of health related quality of life after dose-dense chemotherapy vs standard three-weekly adjuvant chemotherapy (PANTHER study)
A randomized controlled lifestyle intervention in BRCA mutation carriers
HERITAGE: a phase III study of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin
Total preoperative NACT vs sandwich NACT: systematic review and meta-analysis
Pembrolizumab for metastatic triple-negative breast cancer: long-lasting responses in the KEYNOTE-012 study
Phase 1b/2 study of eribulin mesylate plus pembrolizumab in metastatic triple-negative breast cancer
Efficacy and safety of ribociclib + letrozole in elderly patients with advanced breast cancer in MONALEESA-2
Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients
Please login below to download this issue (PDF)